National utilization data for hematopoietic stem-cell transplantation (HSCT) for childhood cancers in the United States have not been reported. We identified cancer encounters for children aged 18 years and younger from 1997 to 2001 in US nonfederal, acute care hospitals. We compared patient, hospital, and resource use characteristics and in-patient mortality associated with HSCT and non-HSCT encounters, estimated the number of HSCT encounters by stem-cell source and cancer type, and examined resource use and mortality in each category. We identified 461 175 cancer encounters, of which 6380 (1.4%) were HSCT encounters. There was wide variation in resource use and mortality by stem-cell source and cancer type. Of note, 17% of HSCT encounters were for patients with acute lymphoblastic leukemia without remission or sarcoma, conditions for which there is little evidence of benefit from HSCT in children. These encounters were associated with high in-patient mortality and long lengths of stay. Also, we observed an increasing use of cord blood over the study period. Future research should examine potentially important sociodemographic differences in patients undergoing HSCT compared to those who do not. Additional analyses incorporating disease stage and severity are needed.
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Hematopoietic stem-cell transplantation (HSCT) is an established therapy for many childhood cancers. 1 Stem cells from autologous or allogeneic bone marrow, peripheral blood, or cord blood may be used to reconstitute hematopoiesis in malignancies that affect the hematopoietic system or to avert hematopoietic toxicity associated with chemoradiotherapy. However, the relative frequencies of autologous and allogeneic transplantations and use of different stem-cell sources in childhood cancers are unknown. Also unknown is the frequency of HSCT by type of childhood cancer. In acute lymphoblastic leukemia (ALL), allogeneic HSCT is appropriate for some high-risk patients in first remission and for patients in subsequent remissions. [2] [3] [4] HSCT is also an established therapy for acute myeloid leukemia (AML) in first remission in children with matched related donors, 5, 6 but there is no conclusive evidence that autologous HSCT improves outcomes compared to aggressive chemotherapy in children without matched related donors. 7 For children with primary refractory acute leukemia, HSCT is the only known potentially curative therapy, 8, 9 although certain subgroups of patients with relapsed acute leukemia may benefit. [10] [11] [12] [13] There is good evidence that autologous HSCT improves survival for children with metastatic neuroblastoma 14 and in some malignant brain tumors, including medulloblastomas, high-grade astrocytomas, and supratentorial primitive neuroectodermal tumors. 15 Patients with relapsed but chemosensitive Hodgkin's disease and those with nonHodgkin's lymphoma also have improved survival with high-dose chemotherapy and HSCT. 16, 17 There is little or conflicting evidence supporting the use of HSCT in sarcomas, including Ewing's sarcoma and rhabdomyosarcoma. [18] [19] [20] [21] As HSCT in the context of childhood cancers is relatively uncommon, it is difficult to study utilization patterns on an institutional or even regional level. National and international databases may provide opportunities to describe utilization, but most existing data sources are limited. [22] [23] [24] [25] [26] [27] [28] [29] [30] The Surveillance, Epidemiology, and End Results (SEER) database tracks cancer incidence, mortality, and survival in the United States, but does not follow HSCT use or outcomes. 23, 24 The International Bone Marrow Transplant Registry contains outcome data on blood and bone marrow transplantation, 22, 26, 27 but only selected centers participate. Also, the data are not weighted to provide national estimates of utilization and outcomes in the United States, and the registry does not include data on costs and length of stay during admissions for HSCT. Finally, although the National Marrow Donor Program collects data on outcomes and selected post transplant complications in the United States, the data are restricted to unrelated donor transplants facilitated by the program. 25 The value of administrative data for investigating a wide range of topics is being increasingly recognized. [31] [32] [33] The Nationwide In-patient Sample (NIS) provides a nationally representative sample of the US population large enough to allow study of rare procedures and conditions. 34 The database includes detailed information on characteristics of HSCT encounters, including diagnosis and procedure codes, length of stay, charges, and mortality. As HSCT in childhood cancers is an in-patient procedure, hospital claims databases such as the NIS provide relatively comprehensive data. Thus, the NIS offers an efficient and effective means of describing the use of HSCT in children with cancer.
We examined the use of HSCT in children with cancer using NIS data from 1997 to 2001. Specifically, we examined patient characteristics associated with HSCT encounters, including charges, length of stay, and mortality. We also examined the frequency of HSCT procedures by stem-cell source and cancer diagnosis.
Patients and methods
Data are from the NIS for the 5 years from 1997 to 2001. The NIS is part of the Healthcare Cost and Utilization Project, and the data sets used in this study contain information on approximately 7 million discharges from a sample of more than 1000 hospitals in up to 33 states (Table 1) . The NIS approximates a 20% stratified probability sample representative of nonfederal, acute care hospitals in the United States. The sampling strata are based on geographic region, urban-rural status, and teaching status (within region), bed size category (within region, urban-rural status, and teaching status), and ownership (within region, urban-rural status, teaching status, and bed size category). 35 The complex survey design enables extrapolation of the data to pediatric discharges involving HSCT from 1997 to 2001.
Only data for patients aged 18 years and younger with cancer-related hospital encounters were included in the analysis. We identified cancer and HSCT encounters using the NIS Clinical Classification Software (CCS), which collapses International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and procedure codes into a manageable number of clinically meaningful categories. 35 As the 1997 NIS did not include the CCS, we mapped primary and secondary ICD-9-CM codes for each encounter to a master file of all ICD-9-CM codes and their corresponding CCS categories. We defined cancer encounters as encounters with a primary or secondary CCS diagnosis code between 1 and 45. HSCT encounters had a primary or secondary CCS procedure code of 64. We further categorized HSCT encounters as allogeneic, autologous, bone marrow transplant, not otherwise specified, and multiple HSCT procedures on the basis of primary and secondary ICD-9-CM procedure codes. We also grouped the encounters by type of cancer according to primary and secondary ICD-9-CM and CCS codes. Table 2 shows the categorization scheme for HSCT procedures and cancer diagnoses and how we defined encounters associated with mechanical ventilation.
Statistical analysis
We compared demographic, regional, and resource use characteristics associated with HSCT and non-HSCT cancer encounters. Encounter characteristics included patient age, gender, and race/ethnicity; median income in the patient's zip code; hospital characteristics, including geographic region, urban-rural status, and teaching status; payer for the encounter; resource use associated with the encounter (ie mean length of stay, charges); and proportion of encounters associated with in-patient death and mechanical ventilation. Definitions of all categorical variables (except mechanical ventilation) are described in greater detail elsewhere. 35 We compared continuous variables and dichotomous categorical variables using logistic regression models that accounted for sample design and clustering of patients within hospitals. 36 Standard errors for mean age, mean charges per encounter, and mean in-patient days per encounter were also estimated to account for sample design and clustering of patients within hospitals. Comparison of distributions of categorical variables with more than two values (ie race/ethnicity, payer, and geographic region) was based on w 2 tests for equality of weighted proportions. We also estimated the number of HSCT encounters, resource use, and in-patient mortality by stem-cell source and by disease.
We calculated national estimates of encounters by summing the number of cancer or HSCT encounters weighted to represent the spectrum of all hospitals or patients over all discharges. All reported proportions are based on an annual average of 5-year cumulative data. Specifically, we first estimated the cumulative number of encounters during the 5-year period, and then divided the estimate by 5 to obtain an annual average. We produced estimates of total annual charges and total annual inpatient days in a similar fashion. The estimates of mean age, mean charges per encounter, and mean in-patient days per encounter were averaged using the 5-year cumulative data.
Discharge weights for national estimates of total charges were introduced in 2000. In our estimate of charges, we used the general discharge weights for years 1997, 1998, 1999, and 2001 , and the charge-specific discharge weights for 2000. The categories for median household income for patient zip code were redefined in the years after 1997. We used a 1997 median household income variable to create income categories comparable to those used in later years.
All analyses were performed using SAS version 8.2 (SAS Institute, Cary, NC, USA). The institutional review board of Duke University Medical Center approved the study. Table 3 shows characteristics of all in-patient encounters for children with cancer and compares characteristics of inpatient HSCT encounters to characteristics of non-HSCT encounters. From 1997 to 2001, there were an estimated 461 175 cancer encounters, and 6380 of these were for HSCT. On average, there were 1276 HSCT encounters per year (1.4% of all encounters). Compared to non-HSCT encounters, a higher proportion of HSCT encounters were among boys and among patients living in zip codes with median income greater than $45 000. A larger proportion of HSCT encounters were covered by private insurance, including health maintenance organizations, and a smaller proportion were reimbursed by Medicaid or self-pay, compared to non-HSCT encounters. Almost all cancer encounters were in urban hospitals, and the large majority was in teaching hospitals.
Results
Although HSCT encounters accounted for only 1.4% of all cancer encounters, they accounted for 8.5% of all inpatient days for cancer encounters and 12.1% of all inpatient charges for cancer encounters. The mean length of stay for HSCT encounters was 6.6 times higher than the mean length of stay for non-HSCT encounters. The mean length of stay for HSCT encounters did not vary significantly in the years under study (range, 35.1-38.4 days). The mean charges per HSCT encounter were $204 026, 9.7 times higher than mean charges per non-HSCT encounter. Moreover, during HSCT encounters, 7.3% of patients were placed on mechanical ventilation, a rate almost five times higher than for non-HSCT encounters (1.5%; Po0.001). The in-patient death rate for HSCT encounters was 10.0%, eight times higher than for non-HSCT encounters.
Transplantation by stem-cell source
Of the 1276 HSCT encounters, 51.1% were coded as single allogeneic transplants, and 46.4% were coded as single autologous transplants (Table 4) . Of the allogeneic procedures, bone marrow was the source coded most frequently (34.8% of all HSCT encounters). Of the autologous procedures, autologous peripheral blood stem cells were the source in 40.3% of HSCT encounters.
Although cord blood was coded as the source in only 4.9% of HSCT encounters from 1997 to 2001, its use increased dramatically during the time period studied, from an estimate near zero in 1997 to 109 per year in 2001 (data not shown). These procedures were performed almost exclusively in patients with leukemia or non-Hodgkin's lymphoma. On average, length of stay for allogeneic HSCT was 44.9 days, charges per encounter were $258 554, and in-patient mortality was 15%. As shown in Table 4 , these estimates were higher than the estimates for autologous HSCT. Cord blood was the allogeneic source associated with the highest in-patient mortality (27.5%). Of note, there were 27 encounters per year on average for which more than one HSCT procedure was coded. These infrequent encounters had the highest mean length of stay (63.4 days) and charges per encounter ($343 217). Although in-patient mortality for these procedures was high (17.2%), it was comparable to in-patient mortality for all allogeneic procedures.
Transplantation and outcomes by cancer diagnosis
As shown in Table 5 , leukemias were the most frequent diagnoses for HSCT encounters, accounting for an estimated 596 encounters per year (46.7%). Of these, 95% used allogeneic stem-cell sources (data not shown). Of all cord blood procedures, 75% were performed for leukemia, but these represented only 8% of all transplants for leukemia (data not shown). Patients with acute or unspecified leukemia had the highest in-patient death rate (approximately 15-17%). Patients with CML had an inpatient death rate of only 7.7%. Patients with leukemia also consumed the most health-care resources, with all categories of leukemia having mean lengths of stay greater than 40 days and charges per encounter near or exceeding $250 000. Of the estimated 290 HSCT encounters per year for ALL, an estimated 133 (45.9%) were coded as ALL without remission. Among HSCT encounters for patients with acute leukemia, encounters for ALL without remission were associated with the highest in-patient mortality (21.3%), mean length of stay (48.7 days), and charges per encounter ($294 621).
Among HSCT encounters not associated with leukemia (680 per year or 53.3% of all HSCT encounters), adrenal cancer (presumed subset of all neuroblastoma) was the most frequent ICD-9-CM code (14.5% of all HSCT encounters), followed by central nervous system tumors, sarcomas, non-Hodgkin's lymphoma, and Hodgkin's dis- Table 4 Outcomes by source of HSCT ease. In all, 13% of HSCT encounters were not easily classifiable by ICD-9-CM diagnosis code. Stem-cell sources were almost exclusively autologous for adrenal tumors, central nervous system tumors, and sarcomas (data not shown). For non-Hodgkin's lymphoma, allogeneic and autologous transplants were each about 50%, and for Hodgkin's disease, autologous transplants predominated (approximately 80%; data not shown). In-patient mortality for patients without leukemia was lower than for patients with leukemia. The highest mortality for patients without leukemia was for patients with non-Hodgkin's lymphoma (7.4%), and the lowest was for patients with sarcomas (1.5%). These HSCT encounters also accounted for fewer resources than did leukemia-related HSCT encounters, with mean lengths of stay less than 30 days and charges per encounter less than $170 000.
Discussion
In this retrospective study of national utilization patterns of HSCT in children, we found that HSCT encounters, although relatively uncommon, account for 12% of all inpatient charges for children with cancer. Moreover, inpatient mortality is eight times higher for HSCT encounters than for non-HSCT encounters. Three findings were particularly striking. First, an average of approximately 17% of HSCT encounters were in patients with diagnoses of ALL without remission and sarcoma. There is little evidence that patients with either of these diagnoses benefit from HSCT. Notably, encounters for ALL without remission were associated with high in-patient mortality and long lengths of stay. Second, we observed an increasing use of cord blood over the study period. Third, we observed potentially important differences among patients undergoing HSCT. In particular, a lower proportion of HSCT encounters were for female patients, patients living in lower-income zip codes, black patients, and patients with Medicaid coverage, as compared to non-HSCT cancer encounters. We estimate that 133 of the total 1276 HSCT encounters in each of the years under study were for encounters coded as ALL without remission, and 86 HSCT encounters were for encounters coded as sarcoma. Encounters for ALL without remission were associated with the highest inpatient mortality (21%) and mean length of stay (48.7 days). As it is unclear whether certain children with ALL without remission 37 and children with sarcoma benefit from HSCT, [18] [19] [20] use of the procedure in these patients raises concern. However, because the reports cited were not available during the time frame of our study, they would not have influenced practice decisions. In addition, it may be that the procedures were performed in the context of clinical trials designed to assess the efficacy of innovative approaches to treating high-risk groups of patients. Unfortunately, the NIS data do not allow us to examine that possibility.
Encounters by stem-cell source were distributed equally between allogeneic and autologous sources. Most HSCT procedures for leukemia were allogeneic, and those for solid tumors were autologous (data not shown). Although umbilical cord blood was used in only 4.9% of HSCT procedures over the 5-year period, its use has increased steadily. In 2001, 8.5% of HSCT encounters in children with cancer used umbilical cord blood.
Proportions of HSCT encounters for female patients, patients from lower-income zip codes, patients covered by Medicaid, and black patients were lower than among non-HSCT encounters. Future research using data sets that include both disease and demographic variables are needed to determine whether gender, income, insurance coverage, or race/ethnicity independently influence access to HSCT procedures for childhood cancers.
The primary strength of our study was the use of a national discharge database, which allowed for estimation of total numbers of transplants in children with cancer by diagnosis and stem-cell source, and allowed comparison of demographic features between patients undergoing transplantation and those with encounters not associated with HSCT.
Our analysis has some limitations. First, the NIS is an administrative data source and, as such, lacks detailed clinical information. No national data set contains linked clinical and administrative data concerning children with cancer. Such data sets do exist for Medicare patients; SEER clinical data linked with Medicare administrative data have been a powerful tool for analyzing access and quality of care in elderly patients. [38] [39] [40] [41] Miscoding of major cancer diagnoses and HSCT procedures is another possible limitation. Although cancer diagnoses are likely to be well coded, remission status may not be even though ICD-9 codes exist. Our finding that half of leukemia transplants are performed in patients without remission needs to be confirmed with clinical data in future research. HSCT procedures tend to be coded well because admissions for such procedures are reimbursed maximally only when they are coded properly. Another potential limitation is that HSCT is a rare event in the NIS, and it is possible that the patterns we describe here pertain only to the states sampled in the NIS. Nevertheless, comparative analyses of a broad range of estimates from the NIS, the National Hospital Discharge Survey, and the Medicare MedPAR file suggest that NIS estimates are consistent with the other two databases. 36 Finally, the NIS does not contain unique patient identifiers, and we were only able to examine inhospital morbidity and mortality. Deaths and complications that occurred after discharge and those that occurred on readmission were not captured.
Our analysis suggests that many HSCT procedures are used in clinical populations -including children with ALL without remission and children with sarcoma -for which evidence is limited. In addition, the data suggest potentially important sociodemographic differences in patients undergoing HSCT as compared to those who do not. Additional analyses that incorporate disease stage and severity are needed.
